Bpi Labs Drug Patent Portfolio
Bpi Labs owns 1 orange book drug protected by 3 US patents Given below is the list of Bpi Labs's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283197 | More potent and less toxic formulations of epinephrine and methods of medical use | 15 Aug, 2034 | Active |
| US10004700 | More potent and less toxic formulations of epinephrine and methods of medical use | 14 Aug, 2034 | Active |
| US10039728 | More potent and less toxic formulations of epinephrine and methods of medical use | 14 Aug, 2034 | Active |
Latest Legal Activities on Bpi Labs's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bpi Labs.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 30 Aug, 2023 | US9283197 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 26 Jan, 2022 | US10039728 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 08 Dec, 2021 | US10004700 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 12 Oct, 2021 | US11141540 |
|
Recordation of Patent Grant Mailed
Critical
| 12 Oct, 2021 | US11141540 |
|
Email Notification
Critical
| 23 Sep, 2021 | US11141540 |
|
Issue Notification Mailed
Critical
| 22 Sep, 2021 | US11141540 |
| Dispatch to FDC | 14 Sep, 2021 | US11141540 |
|
Application Is Considered Ready for Issue
Critical
| 14 Sep, 2021 | US11141540 |
|
Issue Fee Payment Verified
Critical
| 10 Sep, 2021 | US11141540 |
|
Issue Fee Payment Received
Critical
| 10 Sep, 2021 | US11141540 |
|
Email Notification
Critical
| 11 Jun, 2021 | US11141540 |
|
Mail Notice of Allowance
Critical
| 11 Jun, 2021 | US11141540 |
|
Electronic Review
Critical
| 11 Jun, 2021 | US11141540 |
|
Notice of Allowance Data Verification Completed
Critical
| 09 Jun, 2021 | US11141540 |
Bpi Labs's Drug Patent Litigations
Bpi Labs's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 26, 2019, against patent number US9283197. The petitioner Adamis Pharmaceuticals Corporation, challenged the validity of this patent, with Belcher Pharmaceuticals, LLC as the respondent. Click below to track the latest information on how companies are challenging Bpi Labs's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9283197 | April, 2019 |
Terminated-Settled
(02 Aug, 2019)
| Belcher Pharmaceuticals, LLC | Adamis Pharmaceuticals Corporation |
Bpi Labs's Family Patents
Bpi Labs Drug List
Given below is the complete list of Bpi Labs's drugs and the patents protecting them.
1. Epinephrine
Epinephrine is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283197 | More potent and less toxic formulations of epinephrine and methods of medical use |
15 Aug, 2034
(9 years from now)
| Active |
| US10004700 | More potent and less toxic formulations of epinephrine and methods of medical use |
14 Aug, 2034
(9 years from now)
| Active |
| US10039728 | More potent and less toxic formulations of epinephrine and methods of medical use |
14 Aug, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epinephrine's drug page